Immunotherapy for pediatric brain tumors: past and present

被引：30

作者：

Foster, Jessica B. ^{[1
,2
]}

Madsen, Peter J. ^{[3
]}

Hegde, Meenakshi ^{[4
,5
]}

Ahmed, Nabil ^{[4
,5
]}

Cole, Kristina A. ^{[1
,2
]}

Maris, John M. ^{[1
,6
]}

Resnick, Adam C. ^{[3
,7
]}

Storm, Phillip B. ^{[3
,7
]}

Waanders, Angela J. ^{[8
]}

机构：

[1] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA

[2] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA

[3] Childrens Hosp Philadelphia, Div Neurosurg, Philadelphia, PA 19104 USA

[4] Texas Childrens Hosp, Texas Childrens Canc Ctr, Houston, TX 77030 USA

[5] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA

[6] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA

[7] Childrens Hosp Philadelphia, Ctr Data Driven Discovery Biomed, Philadelphia, PA 19104 USA

[8] Ann & Robert H Lurie Childrens Hosp Chicago, Div Oncol, Chicago, IL 60611 USA

来源：

NEURO-ONCOLOGY | 2019年 / 21卷 / 10期

关键词：

brain tumor; immunotherapy; pediatric; ACTIVATED KILLER-CELLS; WT1 PEPTIDE VACCINATION; MALIGNANT PRIMARY BRAIN; T-CELLS; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PEPTIDES; HEMATOLOGICAL MALIGNANCIES; IMMUNE-RESPONSES; YOUNG-ADULTS; GLIOBLASTOMA;

D O I：

10.1093/neuonc/noz077

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The field of cancer immunotherapy has progressed at an accelerated rate over the past decade. Pediatric brain tumors thus far have presented a formidable challenge for immunotherapy development, given their typically low mutational burden, location behind the blood-brain barrier in a unique tumor microenvironment, and intratumoral heterogeneity. Despite these challenges, recent developments in the field have resulted in exciting preclinical evidence for various immunotherapies and multiple clinical trials. This work reviews the history and advances in active immunotherapy, checkpoint blockade, and adoptive T-cell therapy for pediatric brain tumors, including ongoing clinical trials.

引用

页码：1226 / 1238

页数：13

共 50 条

[21] Cancer immunotherapy: The past, the present and the future
Parish, CR
IMMUNOLOGY AND CELL BIOLOGY, 2003, 81 (02): : 106 - 113
[22] BCG Immunotherapy, past, present and future
Rodriguez Faba, Oscar
Huguet Perez, Jorge
Pisano, Francesca
Parada, Ruben
Palou, Joan
Breda, Alberto
ARCHIVOS ESPANOLES DE UROLOGIA, 2020, 73 (10): : 918 - 928
[23] Allergen Immunotherapy: Past, Present, and Future
Jutel, Marek
Kosowska, Anna
Smolinska, Sylwia
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2016, 8 (03) : 191 - 197
[24] Melanoma immunotherapy: Past, present, and future
Saleh, F
Renno, W
Klepacek, N
Ibrahim, G
Asfar, S
Dashti, H
Romero, P
Dashti, A
Behbehani, A
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (27) : 3461 - 3473
[25] Immunotherapy of melanoma - past, present and future
Hersey, Peter
CANCER FORUM, 2005, 29 (02) : 90 - 92
[26] Transdermal immunotherapy: Past, present and future
Marian Szczepanik
Monika Majewska-Szczepanik
Pharmacological Reports, 2016, 68 : 773 - 781
[27] Allergen immunotherapy: past, present and future
Stephen R. Durham
Mohamed H. Shamji
Nature Reviews Immunology, 2023, 23 : 317 - 328
[28] Transdermal immunotherapy: Past, present and future
Szczepanik, Marian
Majewska-Szczepanik, Monika
PHARMACOLOGICAL REPORTS, 2016, 68 (04) : 773 - 781
[29] GENETIC CHARACTERIZATION OF ADULT AND PEDIATRIC BRAIN TUMORS: UNLOCKING IMMUNOTHERAPY TARGETS
Silva, D. N.
Rovesti, G.
Yao, H.
Maravelia, P.
Gatto, F.
Sandvik, U.
Fernandez, A.
Chiavelli, C.
Dominici, M.
Sallberg, M.
Buggert, M.
Groenlund, H.
Nilsson, O.
Pasetto, A.
CYTOTHERAPY, 2024, 26 (06) : E26 - E27
[30] Transcriptomic observations of intra and extracellular immunotherapy targets for pediatric brain tumors
Frederico, Stephen C.
Raphael, Itay
Nisnboym, Michal
Huq, Sakibul
Schlegel, Brent T.
Sneiderman, Chaim T.
Jackson, Sydney A.
Jain, Anya
Olin, Michael R.
Rood, Brian R.
Pollack, Ian F.
Hwang, Eugene I.
Rajasundaram, Dhivyaa
Kohanbash, Gary
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (11) : 1411 - 1420

← 1 2 3 4 5 →